News >

Expert Explores Future of CDK4/6 Inhibitors in Breast Cancer

Brandon Scalea
Published: Thursday, Jan 10, 2019

Dr Matthew Goetz

Matthew Goetz, MD
FDA approvals of 3 CDK4/6 inhibitors have added important treatment options to the armamentarium for patients with hormone receptor (HR)–positive breast cancer, but the future will focus on defining mechanisms of acquired and de novo resistance to these agents, said Matthew P. Goetz, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication